Resultados de procura - X. Cynthia

Limitar resultados
  1. 1
    Letrozole in the neoadjuvant setting: the P024 trial

    Letrozole in the neoadjuvant setting: the P024 trial por Matthew J. Ellis, X. Cynthia

    Publicado 2007
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy

    Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy por Parvin F. Peddi, Matthew J. Ellis, X. Cynthia

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

    Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics por X. Cynthia, James W. Janetka, Helen Piwnica‐Worms

    Publicado 2010
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  4. 4
    Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer

    Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer por Sandeep Rajput, Nimmish Khera, Zhanfang Guo, Jeremy Hoog, Shunqiang Li, X. Cynthia

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians

    Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians por Foluso O. Ademuyiwa, Tao Yu, Jingqin Luo, Katherine N. Weilbaecher, X. Cynthia

    Publicado 2016
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in <scp>US</scp> women 18 to 64 years old

    Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in <scp>US</scp> women 18 to 64 years old por Christine D. Hsu, Xiaoyan Wang, David V. Habif, X. Cynthia, Kimberly Johnson

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    <i>HER2</i>-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor

    <i>HER2</i>-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor por Noa Ben-Baruch, Ron Bose, Shyam M. Kavuri, X. Cynthia, Matthew J. Ellis

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models

    Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models por Siguang Xu, Shunqiang Li, Zhanfang Guo, Jingqin Luo, Matthew J. Ellis, X. Cynthia

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1.

    Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. por Dror I. Baruch, J A Gormely, X. Cynthia, R J Howard, B L Pasloske

    Publicado 1996
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy

    Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy por Farrokh Dehdashti, Ningying Wu, X. Cynthia, Michael Naughton, John A. Katzenellenbogen, Barry A. Siegel

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Protein Subcellular Localization Profiling of Breast Cancer Cells by Dissociable Antibody MicroArray (DAMA) Staining

    Protein Subcellular Localization Profiling of Breast Cancer Cells by Dissociable Antibody MicroArray (DAMA) Staining por Fu, Guanyuan, Song, X. Cynthia, Yang, Xufen, Peng, Tao, Wang, Yingjian, Zhou, G. Wayne

    Publicado 2010
    Ligazón do recurso Ligazón do recurso Ligazón do recurso
    Text
    Engadir a favoritos
    Gardado en:
  12. 12
    Cost–effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice

    Cost–effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice por Schackman, Bruce R, Haas, David W, Park, Sanghee S, Li, X Cynthia, Freedberg, Kenneth A

    Publicado 2015
    Ligazón do recurso Ligazón do recurso Ligazón do recurso
    Text
    Engadir a favoritos
    Gardado en:
  13. 13
    US breast cancer mortality trends in young women according to race

    US breast cancer mortality trends in young women according to race por Foluso O. Ademuyiwa, Feng Gao, Hao Lin, Daniel Morgensztern, Rebecca Aft, X. Cynthia, Matthew J. Ellis

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer

    Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer por Beomyoung Cho, Yunan Han, Min Lian, Graham A. Colditz, Jason D. Weber, X. Cynthia, Ying Liu

    Publicado 2021
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Neoadjuvant Chemotherapy Is Associated with Improved Survival Compared with Adjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Only after Complete Pathologic Response

    Neoadjuvant Chemotherapy Is Associated with Improved Survival Compared with Adjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Only after Complete Pathologic Resp... por Carla S. Fisher, X. Cynthia, William E. Gillanders, Rebecca Aft, Timothy J. Eberlein, Feng Gao, Julie A. Margenthaler

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

    Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer por César Sánchez, X. Cynthia, Robert J. Crowder, Therese Guintoli, Chanpheng Phommaly, Feng Gao, Lin Li, Matthew J. Ellis

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells

    Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells por Venkataswarup Tiriveedhi, Timothy P. Fleming, Peter S. Goedegebuure, Michael Naughton, X. Cynthia, Craig Lockhart, Feng Gao, William E. Gillanders, T. Mohanakumar

    Publicado 2012
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Risk of Breast Cancer With Prolactin Elevating Antipsychotic Drugs

    Risk of Breast Cancer With Prolactin Elevating Antipsychotic Drugs por Tahir Rahman, John M. Sahrmann, Margaret A. Olsen, Katelin B. Nickel, J. Philip Miller, X. Cynthia, Richard A. Grucza

    Publicado 2021
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma

    Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma por X. Cynthia, Martha Q. Lacy, John F. Rompala, Angela Dispenzieri, S. Vincent Rajkumar, Philip R. Greipp, Rafaël Fonseca, Robert A. Kyle, Morie A. Gertz

    Publicado 2004
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance)

    Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase... por Harold J. Burstein, Constance Cirrincione, William T. Barry, Helen K. Chew, Sara M. Tolaney, Diana Lake, X. Cynthia, Kimberly Blackwell, Eric P. Winer, Clifford A. Hudis

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: